97 related articles for article (PubMed ID: 16580160)
1. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
Rubinstein I; Ikezaki H; Onyüksel H
Int J Pharm; 2006 Jun; 316(1-2):144-7. PubMed ID: 16580160
[TBL] [Abstract][Full Text] [Related]
2. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension.
Onyüksel H; Séjourné F; Suzuki H; Rubinstein I
Peptides; 2006 Sep; 27(9):2271-5. PubMed ID: 16621151
[TBL] [Abstract][Full Text] [Related]
3. Liposomal vasoactive intestinal peptide.
Sethi V; Onyüksel H; Rubinstein I
Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ.
Suzuki H; Noda Y; Gao XP; Séjourné F; Alkan-Onyuksel H; Paul S; Rubinstein I
Am J Physiol; 1996 Jul; 271(1 Pt 2):H282-7. PubMed ID: 8760186
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.
Gao XP; Noda Y; Rubinstein I; Paul S
Life Sci; 1994; 54(15):PL247-52. PubMed ID: 8152324
[TBL] [Abstract][Full Text] [Related]
6. Liposomal VIP potentiates DNA synthesis in cultured oral keratinocytes.
Rubinstein I; Dagar S; Sethi V; Krishnadas A; Onyüksel H
Peptides; 2001 Apr; 22(4):671-5. PubMed ID: 11311738
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo.
Séjourné F; Suzuki H; Alkan-Onyüksel H; Gao XP; Ikezaki H; Rubinstein I
Am J Physiol; 1997 Jul; 273(1 Pt 2):R287-92. PubMed ID: 9249562
[TBL] [Abstract][Full Text] [Related]
8. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
Ikezaki H; Paul S; Alkan-Onyüksel H; Patel M; Gao XP; Rubinstein I
Am J Physiol; 1998 Jul; 275(1):R56-62. PubMed ID: 9688960
[TBL] [Abstract][Full Text] [Related]
9. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
Lajavardi L; Camelo S; Agnely F; Luo W; Goldenberg B; Naud MC; Behar-Cohen F; de Kozak Y; Bochot A
J Control Release; 2009 Oct; 139(1):22-30. PubMed ID: 19481575
[TBL] [Abstract][Full Text] [Related]
10. [Protective effects of vasoactive intestinal peptide on septic shock rats].
Qiu JF; Zhang ZQ; Chen W; Wu ZY
Zhonghua Wai Ke Za Zhi; 2007 Feb; 45(3):196-9. PubMed ID: 17498382
[TBL] [Abstract][Full Text] [Related]
11. Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension.
Rubinstein I
Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):565-9. PubMed ID: 16076268
[TBL] [Abstract][Full Text] [Related]
12. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
Stark B; Andreae F; Mosgoeller W; Edetsberger M; Gaubitzer E; Koehler G; Prassl R
Eur J Pharm Biopharm; 2008 Sep; 70(1):153-64. PubMed ID: 18555674
[TBL] [Abstract][Full Text] [Related]
13. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
14. Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
Ikezaki H; Onyüksel H; Rubinstein I
Am J Physiol; 1998 Aug; 275(2):R588-95. PubMed ID: 9688697
[TBL] [Abstract][Full Text] [Related]
15. Inhalable liposomal formulation for vasoactive intestinal peptide.
Hajos F; Stark B; Hensler S; Prassl R; Mosgoeller W
Int J Pharm; 2008 Jun; 357(1-2):286-94. PubMed ID: 18328650
[TBL] [Abstract][Full Text] [Related]
16. Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension.
Haydar S; Sarti JF; Grisoni ER
J Pediatr Surg; 2007 May; 42(5):758-64. PubMed ID: 17502178
[TBL] [Abstract][Full Text] [Related]
17. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A
J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963
[TBL] [Abstract][Full Text] [Related]
18. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies.
Dagar S; Krishnadas A; Rubinstein I; Blend MJ; Onyüksel H
J Control Release; 2003 Aug; 91(1-2):123-33. PubMed ID: 12932644
[TBL] [Abstract][Full Text] [Related]
19. Prolonged anti-hypertensive effects of oral sitaxsentan, a selective ET(A) endothelin receptor antagonist, in spontaneoulsy hypertensive hamsters.
Rubinstein I
Cardiovasc Drugs Ther; 2006 Oct; 20(5):387-90. PubMed ID: 17043751
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.
Lajavardi L; Bochot A; Camelo S; Goldenberg B; Naud MC; Behar-Cohen F; Fattal E; de Kozak Y
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3230-8. PubMed ID: 17591893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
